Le Lézard
Classified in: Health
Subject: FDA

Amerigen Announces U.S. FDA Approval For Generic Penicillamine 250 mg Capsules


LYNDHURST, N.J., May 8, 2019 /PRNewswire/ -- Amerigen Pharmaceuticals Limited ("Amerigen") today announced that Amerigen's Abbreviated New Drug Application ("ANDA") for Penicillamine Capsules USP 250 mg has received final approval from the U.S. Food and Drug Administration. This is the first such ANDA to be approved as a generic equivalent to Bausch Heath's Cuprimine®. The finished product is manufactured for Amerigen in the U.S. where it has already been launched by Amerigen's affiliate, Amerigen Pharmaceuticals, Inc.

Penicillamine Capsules USP are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

John Lowry, Amerigen's President and CEO, commented "We are delighted to launch this first generic of Penicillamine Capsules. This is Amerigen's ninth U.S. product launch and the fourth time we have brought a first generic to market, with important savings for the American healthcare system."

About Amerigen

Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the U.S. and China. The group is controlled by Amerigen Pharmaceuticals Limited. The U.S. regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province.

The group has products on the market currently in both the U.S. and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the U.S. FDA and the Chinese NMPA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the U.S. FDA.

SOURCE Amerigen Pharmaceuticals


These press releases may also interest you

at 14:20
Market OverviewThe exosomes market is expected to register a CAGR of nearly 18.0% during the forecast period, 2019-2024. Read the full report: https://www.reportlinker.com/p05826220/?utm_source=PRN - Certain factors that are driving the market...

at 14:15
The "Global Marine Biotechnology Market" report has been added to ResearchAndMarkets.com's offering. The global marine biotechnology market is expected to grow significantly from USD 3,500.4 million in 2017 to USD 6,500.6 million in 2024, at a CAGR...

at 14:00
As a way to honor veterans this Veterans Day, Cohen Veterans Network (CVN), a national not-for-profit network of mental health clinics for post-9/11 veterans and military families, partnered with StoryCorps to record, preserve, and share the stories...

at 14:00
PRP Science, Florida's leading medical distribution company known for setting the standard in excellence for autologous biologics, is now representing two of the most respected manufacturers in the medical aesthetics arena; Ameia Med and...

at 14:00
Rita M. Gardner, President and CEO of Melmark, Inc. has just been named #37 on The Commonwealth Institute's (TCI) list of the Top 100 Women-Led Businesses in Massachusetts for 2019. This is the second consecutive year Gardner and Melmark have made...

at 13:45
The "Pain Management Devices - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering. The Pain Management Devices market worldwide is projected to grow by US$2.7 Billion, driven by a compounded growth of...



News published on 8 may 2019 at 15:34 and distributed by: